Entries |
Document | Title | Date |
20080214600 | Quaternized Quinuclidine Esters - Compounds of formula (I) | 09-04-2008 |
20080214601 | 2-ALKYLBENZOXAZOLE CARBOXAMIDES AS 5HT3 MODULATORS - Compounds of formulae I and II: | 09-04-2008 |
20080214602 | N-Biarylamides - The invention relates to N-biarylamides useful for the prophylaxis and/or treatment of impairments of perception, concentration, learning and/or memory, and to processes for preparing them, and pharmaceutical compositions containing them. | 09-04-2008 |
20080221155 | Novel quinuclidine derivatives and medicinal compositions containing the same - A compound according to formula (I) | 09-11-2008 |
20080227809 | Arylalkylamine Vanadium (V) Salts for the Treatment and/or Prevention of Diabetes Mellitus - This invention provides compounds and pharmaceutical compositions thereof for treating human type 1 and type 2 diabetes, particularly insulin-resistant diabetes. | 09-18-2008 |
20080242697 | Process for the synthesis of solifenacin - The present invention provides an improved synthetic strategy for the preparation of solifenacin and pharmaceutically acceptable salts thereof. | 10-02-2008 |
20080255187 | 5-HT4 RECEPTOR AGONIST COMPOUNDS - The invention provides novel quinolinone-carboxamide 5-HT | 10-16-2008 |
20080262030 | Organic Compounds - The present invention relates to compounds of formula (I) | 10-23-2008 |
20080287487 | Muscarinic Acetylcholine Receptor Antagonists - Muscarinic Acetylcholine Receptor Antagonists and methods of using them are provided. | 11-20-2008 |
20090005412 | NOVEL QUINUCLIDINE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME - Carbamates of formula (I) or pharmaceutically acceptable salts thereof, including quaternary ammonium salts of formula (II) are disclosed; as well as processes for their preparation, pharmaceutical compositions comprising them and their use in therapy as antagonists of M3 muscarinic receptors. | 01-01-2009 |
20090012116 | Muscarinic Receptor Antagonists - Provided are muscarinic receptor antagonists, which can be useful in treating various diseases of the respiratory, urinary or gastrointestinal system mediated through muscarinic receptors. Also provided are processes for preparing compounds described herein, pharmaceutical compositions comprising compounds described herein, and methods for treating diseases mediated through muscarinic receptors. | 01-08-2009 |
20090018160 | Heterocyclic Compounds with Affinity to Muscarinic Receptors - The present invention relates to heterocyclic compounds of the formula (I) | 01-15-2009 |
20090048290 | 2S,3R)-N-(2-((3-PYRIDINYL)METHYL)-1-AZABICYCLO[2.2.2]OCT-3-YL-BENZYOFURAN-- 2-CARBOXAMIDE, NOVEL SALT FORMS, AND METHODS OF USE THEREOF - The present invention relates to (2S,3R)—N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide, novel salt forms thereof, methods for its preparation, novel intermediates, and methods for treating a wide variety of conditions and disorders, including those associated with dysfunction of the central and autonomic nervous systems. | 02-19-2009 |
20090048291 | Novel Piperidine-4-Acetic Acid Derivatives and Their Use - The present invention is directed to compounds of formula I | 02-19-2009 |
20090054480 | NOVEL QUINUCLIDINE CARBAMATE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME - Carbamates of formula (I) or pharmaceutically acceptable salts thereof, including quaternary ammonium salts of formula (II) are disclosed; as well as processes for their preparation, pharmaceutical compositions comprising them and their use in therapy as antagonists of M3 muscarinic receptors. | 02-26-2009 |
20090062336 | Methods of Diminishing Co-Abuse Potential - Methods of diminishing or eliminating the co-abuse of a methylphenidate drug comprising identifying a patient or patient group suspected or likely to abuse said methylphenidate drug in combination with a substance known or suspected to give rise to l-ethylphenidate or psychotropic effect when ingested in the combination and making available to said patent or patient group said methylphenidate drug substantially free of l-threo methylphenidate. | 03-05-2009 |
20090105298 | Pharmaceutical composition for therapy of interstitial cystitis - A depressant of capsaicin-sensitive sensory nerve, containing quinuclidin-3′-yl 1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylate or a salt thereof as an active ingredient, specifically a therapeutic drug of interstitial cystitis, hypersensitive disorder of the lower urinary tract, and/or abacterial prostatitis. | 04-23-2009 |
20090118326 | Nicotinic Acetylcholine Receptor Modulators - The disclosure provides compounds capable of selectively or non-selectively modulating nicotinic acetylcholine receptors. The compounds, compositions, and methods described herein are useful, for example, in treating patients suffering from various medical conditions including pain, chemical addictions, Parkinson's disease, Alzheimer's disease, and neurodegenerative disorders. In one embodiment, the compounds comprise a 7- to 11-membered azabicyclo ring. | 05-07-2009 |
20090124653 | Muscarinic Acetylcholine Receptor Antagonists - Muscarinic Acetylcholine Receptor Antagonists and methods of using them are provided. | 05-14-2009 |
20090131469 | PHARMACEUTICAL AGENT COMPRISING SOLIFENACIN - There is provided an agent comprising solifenacin succinate in an amount of 5 mg to 10 mg or solifenacin or a pharmaceutically acceptable salt thereof in an amount equimolar to 5 mg to 10 mg of solifenacin succinate for improvement of urinary urgency, pollakiuria and urinary incontinence due to neurogenic bladder caused by neurodegenerative diseases such as cerebrovascular disease or cerebral infarction, brain or spinal cord injury due to trauma, multiple sclerosis, Parkinson's disease, congenital malformation of the nerve system, peripheral neuropathy, and various spine lesions, that is, spinal cord compression and injury due to fracture, cervical and lumbar spondylosis, spondylosis deformans, spondylolisthesis, spinal stenosis, vertebral disk hernia and the like. | 05-21-2009 |
20090131470 | PYRAZOLE-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER AND AUTOIMMUNE DISORDERS - Compounds of formula (I) are inhibitors of PDK1 and CHK1 activity, and of use in the treatment of cancer and autoimmune disorders (I): wherein R | 05-21-2009 |
20090131471 | Compositions useful for treating gastroesophageal reflux disease - The present invention relates to a method of treating GERD in a human subject in need of treatment. The method comprises orally administering to said subject an effective amount of a thieno[3,2-b]pyridine compound of Structural Formula I or a pharmaceutically acceptable salt or N-oxide derivative thereof, wherein the effective amount is from about one to about three daily doses of the compound and the dose is from about 0.2 mg to about 0.5 mg. | 05-21-2009 |
20090163540 | Quinine Sulfate Polymorphs, Processes of Preparing, Compositions and Uses Thereof - Disclosed are new quinine sulfate polymorphs, methods of making the polymorphs as well as formulations prepared therefrom and uses thereof. | 06-25-2009 |
20090163541 | QUINUCLIDINE COMPOUNDS HAVING QUATERNARY AMMONIUM GROUP, ITS PREPARATION METHOD AND USE AS BLOCKING AGENTS OF ACETYLCHOLINE - The invention relates to the quinuclidine compounds of formula I having quaternary ammonium group, its preparation, and the pharmaceutical composition comprising an effective amount of the compound of formula I. The compound and the composition are used to prevent and treat the diseases by blocking acetylcholine receptor. | 06-25-2009 |
20090192187 | DRY POWDER FORMULATION COMPRISING AN ANTICHOLINERGIC DRUG - Pharmaceutical formulation in the form of inhalable dry powder comprising particles of a pharmaceutically acceptable salt of 3-[[[(3-fluorophenyl)[(3,4,5-trifluoro phenyl)methyl]amino]carbonyl]oxy]-1-[2-oxo-2-(2-thienyl)ethyl]-1-azoniabicyclo [2.2.2]octane as active ingredient, and particles of a carrier made of a physiologically acceptable pharmacologically-inert material are effective for the prevention and/or treatment of a respiratory disease such as asthma and COPD. | 07-30-2009 |
20090209579 | INDAZOLES, BENZOTHIAZOLES, AND BENZOISOTHIAZOLES, AND PREPARATION AND USES THEREOF - The present invention relates generally to the field of ligands for nicotinic acetylcholine receptors (nAChR), activation of nAChRs, and the treatment of disease conditions associated with defective or malfunctioning nicotinic acetylcholine receptors, especially of the brain. Further, this invention relates to novel compounds (indazoles and benzothiazoles), which act as ligands for the α7 nAChR subtype, methods of preparing such compounds, compositions containing such compounds, and methods of use thereof. | 08-20-2009 |
20090239900 | QUININE AND QUINIDINE SALTS, METHODS FOR MAKING THEM, AND PHARMACEUTICAL FORMULATIONS COMPRISING THEM - The present invention provides a combination of:
| 09-24-2009 |
20090239901 | METHOD AND COMPOSITIONS FOR TREATMENT OF CEREBRAL MALARIA - A method of treating inflammatory disorders, including cerebral malaria, by administration of modulators of α | 09-24-2009 |
20090239902 | QUININE DOSAGE FORMS AND METHODS OF USE THEREOF - Disclosed herein are quinine formulations and methods of using quinine formulations. Specifically disclosed are methods of using quinine and informing a user of information, including potential adverse effects, the effect of food on quinine's pharmacokinetics, effect of dosing various strengths of quinine, effect of maximum plasma concentrations of quinine in a patient as it relates to adverse events, effects of deviating from the prescribed dosage, etc. | 09-24-2009 |
20090239903 | TETRAHYDROQUINOLINE ANALOGUES AS MUSCARINIC AGONISTS - The present invention relates to tetrahydroquinoline compounds as muscarinic receptor agonists; compositions comprising the same; methods of inhibiting an activity of a muscarinic receptor with said compounds; methods of treating a disease condition associated with a muscarinic receptor using said compounds; and methods for identifying a subject suitable for treatment using said compounds. | 09-24-2009 |
20090258898 | AMIDES OF ACETIC AND PROPIONIC ACIDS - The invention relates to novel amides of acetic and propionic acids, methods for production and use thereof for the production of medicaments for the treatment and/or prophylaxis of diseases and for improving perception, concentration, learning ability and memory. | 10-15-2009 |
20090264461 | Polymorph of (R)-3- (2-Hydroxy-2, 2-Diphenyl -Acetoxy) -1- (Isoxazol-s-ylcarbamoyl-methyl)-1-Azoni A-Bicyclo-[2.2.2] Octane Bromide - A novel polymorphic crystal form of (R)-3-(2-hydroxy-2,2-diphenyl-acetoxy)-1-(isoxazol-3-ylcarbamoyl-methyl)-1-azonia-bicyclo-[2.2.2]octane bromide, designated crystal form Talpha. Methods for preparing same and the use of the crystal form as the active ingredient of medicaments for the treatment of inflammatory or obstructive airways diseases are also described. | 10-22-2009 |
20090298868 | QUINOLINE COMPOUNDS AS MELANOGENESIS MODIFIERS AND USES THEREOF - A method of identification of quinoline compounds (formula I) that modify melanin synthesis (melanogenesis), and the use of such compounds and compositions thereof to control (e.g., inhibit) melanin production are disclosed. | 12-03-2009 |
20090326004 | MUSCARINIC RECEPTOR ANTAGONISTS - The present invention relates generally to muscarinic receptor antagonist, which are useful, among other uses, for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The invention also relates to the process for the preparation of disclosed compounds, pharmaceutical compositions containing the disclosed compounds and the method for treating diseases mediated through muscarinic receptors. Also provided herein are pharmaceutical composition comprising one or more muscarinic receptor antagonists and at least one other active ingredients include, but are not limited to, corticosteroids, beta agonists, leukotriene antagonists, 5-lipoxygenase inhibitors, anti-histamines, antitussives, dopamine receptor antagonists, chemokine inhibitors, p38 MAP Kinase inhibitors, and PDE-IV inhibitors. | 12-31-2009 |
20090326005 | QUININE SULFATE/BISULFATE SOLID COMPLEX; METHODS OF MAKING; AND METHODS OF USE THEREOF - Disclosed are new quinine sulfate/bisulfate solid complexes, methods of making the solid complexes as well as formulations prepared therefrom and uses thereof. | 12-31-2009 |
20100016351 | NICOTINIC ALPHA-7 RECEPTOR LIGANDS AND PREPARATION AND USES THEREOF - The present invention relates generally to the field of ligands for nicotinic acetylcholine receptors (nAChR), activation of nAChRs, and the treatment of disease conditions associated with defective or malfunctioning nicotinic acetylcholine receptors, especially of the brain. Further, this invention relates to novel compounds which act as ligands for the α7 nAChR subtype, methods of preparing such compounds, compositions containing such compounds, and methods of use thereof. | 01-21-2010 |
20100029712 | Irrigation solution and method for inhibition of pain, inflammation, spasm and restenosis - A method and solution for perioperatively inhibiting a variety of pain, inflammation, spasm and restenosis processes resulting from cardiovascular or general surgical, therapeutic and diagnostic procedures. The solution preferably includes multiple pain and inflammation inhibitory agents, including at least one local anesthetic agent, and spasm inhibitory agents at dilute concentration in a physiologic carrier, such as saline or lactated Ringer's solution. Specific preferred embodiments of the solution of the present invention for use in cardiovascular and general vascular procedures also include anti-restenosis agents. | 02-04-2010 |
20100029713 | QUINICLIDINE DERIVATIVES OF (HETERO) ARYLCYCLOHEPTANECARBOXYLIC ACID AS MUSCARINIC RECEPTOR ANTAGONISTS - The invention provides compounds of formula (I) wherein R | 02-04-2010 |
20100035922 | QUINUCLIDINE CARBONATE SALTS AND MEDICINAL COMPOSITION THEREOF - Quinuclidine carbonate derivatives act as muscarinic receptor antagonists and are effective for the prevention and/or treatment of a broncho-obstructive or inflammatory diseases. | 02-11-2010 |
20100048615 | COMBINATIONS COMPRISING ANTIMUSCARINIC AGENTS AND PDE4 INHIBITORS - Combinations comprising (a) a PDE4 inhibitor and (b) an antagonist of M3 muscarinic receptors which is 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane, in the form of a salt having an anion X, which is a pharmaceutically acceptable anion of a mono or polyvalent acid are useful, e.g., for the treatment of respiratory disease, e.g., asthma or chronic obstructive pulmonary diseases. | 02-25-2010 |
20100048616 | COMBINATIONS COMPRISING ANTIMUSCARINIC AGENTS AND PDE4 INHIBITORS - A combination which comprises (a) a PDE4 inhibitor and (b) an antagonist of M3 muscarinic receptors which is (3R)-1-phenethyl-3-(9H-xanthene-9carbonyloxy)-1-azoniabicyclo[2.2.2]octane, in the form of a salt having an anion X, which is a pharmaceutically acceptable anion of a mono or polyvalent acid. | 02-25-2010 |
20100056565 | Heterocyclic Derivatives as M3 Muscarinic Receptors - This invention relates to M3 antagonists of formula (I) wherein R | 03-04-2010 |
20100099701 | ISOQUINOLINONE MODULATORS OF 5-HT3 RECEPTORS - The present invention relates to new isoquinolinone modulators of 5-HT3 receptors, pharmaceutical compositions thereof, and methods of use thereof. | 04-22-2010 |
20100105724 | CRYSTALLINE AND AMORPHOUS FORMS OF PALONOSETRON HYDROCHLORIDE - Amorphous and polymorphic of palonosetron hydrochloride are disclosed that can be characterized by X-ray powder diffraction patterns, thermal properties, purity and methods of manufacture. These forms of palonosetron hydrochloride can be produced from solution or by solid state interconversions. The forms can be used in pharmaceutical formulations: particularly preferred uses of these formulations are in prevention and treatment of nausea and emesis arising from chemotherapy or postoperative side effects. The forms can optionally be used as mixtures of the crystalline and/or amorphous forms. | 04-29-2010 |
20100113510 | QUINUCLIDINOL DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS - The invention provides compounds of formula (I) wherein R | 05-06-2010 |
20100120842 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION - The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on muscarinic receptor modulation, such as via inhibition of acetylcholine esterase (AChE) activity, alone or in combination with another neurogenic agent to stimulate or activate the formation of new nerve cells. | 05-13-2010 |
20100137358 | SOLIFENACIN COMPOSITIONS - Compositions and/or formulations comprising solifenacin or a salt thereof and processes for preparing the same. Certain compositions and formulations contain a stable amorphous form of solifenacin succinate. | 06-03-2010 |
20100152231 | Compositions Useful For Treating Irritable Bowel Syndrome - The present invention relates to a method of treating irritable bowel syndrome with constipation (IBS-c) or irritable bowel syndrome with alternating constipation and diarrhea (IBS-a) in a subject in need of treatment. The method comprises administering to said subject a therapeutically effective amount of a thieno[3,2-b]pyridine compound of Structural Formula I or a pharmaceutically acceptable salt or N-oxide derivative thereof. | 06-17-2010 |
20100152232 | 3-SUBSTITUTED-2(ARYLALKYL)-1-AZABICYCLOALKANES AND METHODS OF USE THEREOF - The present invention relates to 3-substituted-2-(arylalkyl)-1-azabicycloalkanes, methods of preparing the compounds and methods of treatment using the compounds. The azabicycloalkanes generally are azabicycloheptanes, azabicyclooctanes, or azabicyclononanes. The aryl group in the arylalkyl moiety is a 5- or 6-membered ring heteroaromatic, preferably 3-pyridinyl and 5-pyrimidinyl moieties, and the alkyl group is typically a C | 06-17-2010 |
20100152233 | 3-SUBSTITUTED-2(ARYLALKYL)-1-AZABICYCLOALKANES AND METHODS OF USE THEREOF - The present invention relates to 3-substituted-2-(arylalkyl)-1-azabicycloalkanes, methods of preparing the compounds and methods of treatment using the compounds. The azabicycloalkanes generally are azabicycloheptanes, azabicyclooctanes, or azabicyclononanes. The aryl group in the arylalkyl moiety is a 5- or 6-membered ring heteroaromatic, preferably 3-pyridinyl and 5-pyrimidinyl moieties, and the alkyl group is typically a C | 06-17-2010 |
20100240697 | PHARMACEUTICAL COMPOSITION FOR TREATING OVERACTIVE BLADDER - [Problems] To provide a pharmaceutical composition which is useful as a therapeutic agent for overactive bladder. | 09-23-2010 |
20100273825 | SOLID PHARMACEUTICAL COMPOSITION CONTAINING SOLIFENACIN AMORPHOUS FORM - The present invention relates to the provision of a stable solid pharmaceutical composition containing an amorphous form of solifenacin or a pharmaceutically acceptable salt thereof and capable of inhibiting decomposition accompanied by long-term storage, to provide the medical field with a formulation of solifenacin or a pharmaceutically acceptable salt thereof. More particularly, the present invention relates to a solid pharmaceutical composition, comprising an amorphous form of solifenacin or a pharmaceutically acceptable salt thereof, and one stabilizer for amorphous solifenacin or two or more stabilizers for amorphous solifenacin, selected from the group consisting of citric acid or a pharmaceutically acceptable salt (excluding a calcium salt) thereof, sodium pyrosulfite, and a pharmaceutically acceptable salt of ethylenediaminetetraacetic acid. | 10-28-2010 |
20100286195 | NOVEL BENZOOXAZOL-AND BENZOOXATHIOL-2-ONE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS - This invention relates to novel benzooxazol- and benzooxathiol-2-one derivatives useful as monoamine neurotransmitter re-uptake inhibitors. | 11-11-2010 |
20100298371 | PROCESS FOR PREPARING CHEMICALLY AND CHIRALLY PURE SOLIFENACIN BASE AND ITS SALTS - The present invention provides improved processes for preparing chemically and chirally pure Solifenacin base. The present invention also provides for a composition comprising of a salt of Solifenacin having at least 98% purity. The present invention also disclose certain new salts of Solifenacin as well as well as new polymorphic forms of Solifenacin hydrochloride and Solifenacin oxalate, in pure form. | 11-25-2010 |
20100324085 | AZABICYCLIC CARBAMATES AND THEIR USE AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS - The invention relates to novel benzothiophene-, benzofuran-, and indole ureas and to the use thereof for producing medicaments for the treatment and/or prophylaxis of diseases and for improving perception, concentration, learning, and/or memory. | 12-23-2010 |
20110065746 | COMPOSITION OF SOLIFENACIN OR SALT THEREOF FOR USE IN SOLID FORMULATION - A solid pharmaceutical preparation of solifenacin or a salt thereof, the preparation being stable and inhibited from decomposing with time when supplied to clinical fields. In a pharmaceutical preparation containing solifenacin or a salt thereof, the compound in an amorphous form was revealed to be causative of cardinal-drug decomposition with time. The composition for a solid pharmaceutical preparation of solifenacin or a salt thereof contains solifenacin or its salt each in a crystalline from, and the content provided are: a process for producing the composition; and a medicinal composition for solid pharmaceutical preparations which contains solifenacin and an amorphization inhibitor. | 03-17-2011 |
20110071187 | 3-SUBSTITUTED-2(ARYLALKYL)-1-AZABICYCLOALKANES AND METHODS OF USE THEREOF - The present invention relates to 3-substituted-2-(arylalkyl)-1-azabicycloalkanes, methods of preparing the compounds and methods of treatment using the compounds. The azabicycloalkanes generally are azabicycloheptanes, azabicyclooctanes, or azabicyclononanes. The aryl group in the arylalkyl moiety is a 5- or 6-membered ring heteroaromatic, preferably 3-pyridinyl and 5-pyrimidinyl moieties, and the alkyl group is typically a C | 03-24-2011 |
20110071188 | 3-SUBSTITUTED-2(ARYLALKYL)-1-AZABICYCLOALKANES AND METHODS OF USE THEREOF - The present invention relates to 3-substituted-2-(arylalkyl)-1-azabicycloalkanes, methods of preparing the compounds and methods of treatment using the compounds. The azabicycloalkanes generally are azabicycloheptanes, azabicyclooctanes, or azabicyclononanes. The aryl group in the arylalkyl moiety is a 5- or 6-membered ring heteroaromatic, preferably 3-pyridinyl and 5-pyrimidinyl moieties, and the alkyl group is typically a C | 03-24-2011 |
20110071189 | 3-SUBSTITUTED-2(ARYLALKYL)-1-AZABICYCLOALKANES AND METHODS OF USE THEREOF - The present invention relates to 3-substituted-2-(arylalkyl)-1-azabicycloalkanes, methods of preparing the compounds and methods of treatment using the compounds. The azabicycloalkanes generally are azabicycloheptanes, azabicyclooctanes, or azabicyclononanes. The aryl group in the arylalkyl moiety is a 5- or 6-membered ring heteroaromatic, preferably 3-pyridinyl and 5-pyrimidinyl moieties, and the alkyl group is typically a C | 03-24-2011 |
20110124678 | TREATMENT WITH ALPHA 7-SELECTIVE LIGANDS - The present invention includes methods, uses, and selective α7 nAChR agonist compounds for treating or preventing metabolic disorders. | 05-26-2011 |
20110190338 | Compounds and Compositions Useful in the Treatment of Malaria - Provided herein compounds, compositions and methods useful for the treatment of malaria for a subject in need thereof, including compounds of Formula (I), Formula (II), Formula (III), Formula (IV), and Formula (V). | 08-04-2011 |
20110207769 | STABLE CRYSTALLINE SALT OF (R)-3-FLUOROPHENYL-3,4,5-TRIFLUOROBENZYLCARBAMIC ACID 1-AZABICYCLO [2.2.2]OCT-3-YL ESTER - The present invention refers to a stable crystalline salt of (R)-3-fluorophenyl-3,4,5-trifluorobenzylcarbamic acid 1-azabicyclo[2.2.2]oct-3-yl ester and its use as medicament, in particular for the treatment of urinary incontinence or other diseases involving genitourinary disorders | 08-25-2011 |
20110207770 | PHARMACEUTICAL PRODUCT COMPRISING A MUSCARINIC RECEPTOR ANTAGONIST AND A SECOND ACTIVE INGREDIENT - The invention provides a pharmaceutical product, kit or composition comprising a first active ingredient which is a selected muscarinic receptor antagonist, and a second active ingredient which is selected from a phosphodiesterase inhibitor, a modulator of chemokine receptor function, an inhibitor of kinase function, a protease inhibitor, a steroidal glucocorticoid receptor agonist, a non-steroidal glucocorticoid receptor agonist and a purinoceptor antagonist, of use in the treatment of respiratory diseases such as chronic obstructive pulmonary disease and asthma. | 08-25-2011 |
20110245292 | 2-HYDROXY-ETHANESULFONATE SALT - The invention provides (R)-1-[3-(R)-cyclohexyl-hydroxy-phenyl-methyl)-isoxazol-5-ylmethyl]-3-(3-fluoro-phenoxy)-1-azonia-bicyclo[2.2.2]octane 2-hydroxy ethanesulfonate, pharmaceutical compositions containing the compound and its use as a muscarinic antagonists, for the treatment of chronic obstructive pulmonary disease. | 10-06-2011 |
20110245293 | PHARMACEUTICAL PRODUCT COMPRISING A MUSCARINIC RECEPTOR ANTAGONIST AND A BETA-2-ADRENOCEPTOR AGONIST - The invention provides a pharmaceutical product, kit or composition comprising a first active ingredient which is a selected muscarinic receptor antagonist selected, and a second active ingredient which is a β | 10-06-2011 |
20110245294 | METHODS OF IMPROVING QUALITY OF SLEEP - Disclosed herein are methods of treating a patient suffering from overactive bladder (OAB) comprising administering to the patient a combination of antimuscarinic or anticholinergic agent and muscarinic agonist for the treatment of poor quality of sleep in the OAB patient. | 10-06-2011 |
20110257224 | PREPARATION AND THERAPEUTIC APPLICATIONS OF (2S,3R)-N-2-((3-PYRIDINYL)METHYL)-1-AZABICYCLO[2.2.2]OCT-3-YL)-3,5-DIFLUO- ROBENZAMIDE - The present invention relates to compounds that bind to and modulate the activity of neuronal nicotinic acetyl-choline receptors, to processes for preparing these compounds, to pharmaceutical compositions containing these compounds, and to methods of using these compounds for treating a wide variety of conditions and disorders, including those associated with dysfunction of the central nervous system (CNS). | 10-20-2011 |
20110288118 | PHARMACEUTICAL COMPOSITION COMPRISING SOLIFENACIN - Disclosed is a pharmaceutical composition comprising a complex between solifenacin or a pharmaceutically acceptable salt thereof and an ion exchange resin, and an acrylic based polymer. | 11-24-2011 |
20110288119 | Low dose - prov (alpha 7-EVP) - (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide has been found to have procognitive effects in humans at unexpectedly low doses. Thus, (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof can be used at unexpectedly low doses improve cognition. | 11-24-2011 |
20110319444 | QUINUCLIDINE CARBONATE SALTS AND MEDICINAL COMPOSITION THEREOF - Quinuclidine carbonate derivatives act as muscarinic receptor antagonists and are effective for the prevention and/or treatment of a broncho-obstructive or inflammatory diseases. | 12-29-2011 |
20120004258 | QUINUCLIDINE CARBONATE SALTS AND MEDICINAL COMPOSITION THEREOF - Quinuclidine carbonate derivatives act as muscarinic receptor antagonists and are effective for the prevention and/or treatment of a broncho-obstructive or inflammatory diseases. | 01-05-2012 |
20120010236 | QUINUCLIDINE COMPOUNDS HAVING QUATERNARY AMMONIUM GROUP, ITS PREPARATION METHOD AND USE AS BLOCKING AGENTS OF ACETYLCHOLINE - The invention relates to the quinuclidine compounds of formula I having quaternary ammonium group, its preparation, and the pharmaceutical composition comprising an effective amount of the compound of formula I. The compound and the composition are used to prevent and treat the diseases by blocking acetylcholine receptor. | 01-12-2012 |
20120022099 | NOVEL POLYMORPHIC FORMS OF AN AZABICYCLO-TRIFLUOROMETHYL BENZAMIDE DERIVATIVE - The present disclosure is directed to solid forms of the compound of formula (I): | 01-26-2012 |
20120022100 | ORGANIC COMPOUNDS - Disclosed are δ-amino-γ-hydroxy-ω-aryl-alkanoic acid amide compounds of formula (I) | 01-26-2012 |
20120059031 | COMBINATIONS COMPRISING ANTIMUSCARINIC AGENTS AND PDE4 INHIBITORS - A combination which comprises (a) a PDE4 inhibitor and (b) an antagonist of M3 muscarinic receptors which is (3R)-1-phenethyl-3-(9H-xanthene-9carbonyloxy)-1-azoniabicyclo[2.2.2]octane, in the form of a salt having an anion X, which is a pharmaceutically acceptable anion of a mono or polyvalent acid. | 03-08-2012 |
20120095039 | HETEROCYCLIC COMPOUNDS WITH AFFINITY TO MUSCARINIC RECEPTORS - The present invention relates to heterocyclic compounds of formula (I) having affinity to muscarinic receptors, a pharmaceutical composition containing the compounds, as well as the use of the compounds for the preparation of a medicament for treating, alleviating or preventing muscarinic receptor mediated diseases and conditions. | 04-19-2012 |
20120129885 | (2S,3R)-N-(2-((3-PYRIDINYL)METHYL)-1-AZABICYCLO[2.2.2]OCT-3-YL)BENZOFURN-2- -CARBOXAMIDE, NOVEL SALT FORMS, AND METHODS OF USE THEREOF - The present invention relates to (2S,3R)—N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide, novel salt forms thereof, methods for its preparation, novel intermediates, and methods for treating a wide variety of conditions and disorders, including those associated with dysfunction of the central and autonomic nervous systems. | 05-24-2012 |
20120142725 | Combined Use of an Alpha-Adrenergic Receptor Antagonist and an Anti-Muscarinic Agent - The combined use of (R)-5-(2-{[2-(2-ethoxyphenoxy)ethyl]amino}propyl)-2-methoxybenzene-1-sulfonamide (tamsulosin), or its pharmaceutically acceptable salt, and (1S)-1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylic acid (3R)-quinuclidin-3-yl ester (solifenacin), or its pharmaceutically acceptable salt, for the preparation Of a medicament for the improvement of lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH) with a substantial storage component is provided. | 06-07-2012 |
20120157490 | N-BIARYLAMIDES - The invention relates to N-biarylamides useful for the prophylaxis and/or treatment of impairments of perception, concentration, learning and/or memory, and to processes for preparing them, and pharmaceutical compositions containing them. | 06-21-2012 |
20120157491 | MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS - Muscarinic Acetylcholine Receptor Antagonists and methods of using them are provided. | 06-21-2012 |
20120322822 | COMPOSITION CONTAINING CINCHONINE AS AN ACTIVE INGREDIENT FOR PREVENTING AND TREATING OBESITY, DYSLIPIDEMIA, FATTY LIVER, OR INSULIN RESISTANCE SYNDROME - The present invention relates to a composition for preventing or treating obesity, dyslipidemia, fatty liver or insulin resistance syndrome, comprising cinchonine as an active ingredient. The composition of the present invention comprising cinchonine as an active ingredient contributes to not only inhibition of adipocyte differentiation but also reductions of body weight, visceral fat, total cholesterol level, plasma triglyceride level and liver tissue triglyceride level, thereby exerting prevention or treatment efficacies of obesity, hyperlipidemia or fatty liver. In addition, the composition of the present invention induces significant decrease in fasting glucose level and blood insulin level to improve type 2 diabetes, insulin resistance and related metabolic diseases. | 12-20-2012 |
20130005764 | QUININE DOSAGE FORMS AND METHODS OF USE THEREOF - Disclosed herein are quinine formulations and methods of using quinine formulations. Specifically disclosed are methods of using quinine and informing a user of information, including potential adverse effects, the effect of food on quinine's pharmacokinetics, effect of dosing various strengths of quinine, effect of maximum plasma concentrations of quinine in a patient as it relates to adverse events, effects of deviating from the prescribed dosage, etc. | 01-03-2013 |
20130030015 | MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS - Muscarinic Acetylcholine Receptor Antagonists and methods of using them are provided. | 01-31-2013 |
20130040987 | Stereoisomeric Compounds and Methods for the Treatment of Gastrointestinal and Central Nervous System Disorders - The subject invention provides stereoisomeric compounds of formula (X): | 02-14-2013 |
20130131104 | HISTIDINE RICH PROTEIN-2 DIAGNOSTIC TEST FOR CEREBRAL MALARIA - The present inventions relate to accurately identifying a subset of patients within a larger group with malarial parasitemia. In particular, the present inventions provide compositions and methods comprising a malarial protein, histidine rich pro-tein-2 (HRP-2) for determining the general severity of a malarial infection in patients. Specifically, the inventions provide a rapid test comprising a read-out for HRP-2 levels in bodily fluids for determining whether a comatose patient's disease is a result of malaria as opposed to coma of another cause with incidental parasitemia. Specifically, in one preferred embodiment, a rapid test is contemplated as a quantitative rapid test dipstick. Further, these inventions relate to predictive tests for patients at risk for progression of relatively mild malaria disease to the more life-threatening cerebral malaria in addition to determining the etiology of malaria infections in comatose patients. | 05-23-2013 |
20130137717 | Treatment of Cognitive Disorders with (R)-7-Chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-Carboxamide and Pharmaceutically Acceptable Salts Thereof - (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide has been found to have procognitive effects in humans at unexpectedly low doses. Thus, (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof can be used at unexpectedly low doses to improve cognition. | 05-30-2013 |
20130150402 | PHARMACEUTICAL COMPOSITION FOR TREATING OVERACTIVE BLADDER - A pharmaceutical composition comprising (R)-2-(2-aminothiazol-4-yl)-4′-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl}acetanilide or a pharmaceutically acceptable salt thereof and (3R)-quinuclidin-3-yl (1S)-1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylate or a pharmaceutically acceptable salt thereof, as active ingredients, in particular a pharmaceutical composition for improving various symptoms accompanying overactive bladder, such as urinary urgency, pollakiuria and/or urinary incontinence. | 06-13-2013 |
20130197028 | nAChRalpha7 Agonists and nAChRalpha7 Antagonists for Treating Ulcerative Colitis (UC) and Crohn's Disease (CD) - Agonists and antagonists of nAChRα7 and their use as therapeutic agents for treating and managing inflammatory bowel diseases (IBD), such as Crohn's disease (CD) and ulcerative colitis (UC), are disclosed. Agonists and antagonists of nAChRα7 and their use as therapeutic agents for treating and managing inflammatory bowel diseases (IBD), such as Crohn's disease (CD) and ulcerative colitis (UC), are disclosed. | 08-01-2013 |
20130203804 | SOLIFENACIN SALTS - The invention concerns fumarate salts of solifenacin, as well as pharmaceutical compositions comprising fumarate salts of solifenacin. The invention furthermore concerns a process for preparing solifenacin and salts thereof. The fumarate salt provides improved properties over the known solifenacin salts, especially in terms of its stability. The novel process for its preparation is furthermore improved over known processes for preparing solifenacin in that it provides a higher yield and recovers a greater amount of starting material. | 08-08-2013 |
20130231365 | Treatment of Inflammation with Certain Alpha-7 Nicotinic Acid Receptor Agonists in Combination with Acetylcholinesterase Inhibitors - A method for treating inflammation comprising administering to a patient (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide or a pharmaceutically acceptable salt thereof or (R)-7-(2-methoxyphenyl)-N-(quinuclidin-3-yl)benzofuran-2-carboxamide or certain other alpha 7 receptor agonists combination with an acetylcholinesterase inhibitor. | 09-05-2013 |
20130267557 | Combined Use of an Alpha-Adrenergic Receptor Antagonist and an Anti-Muscarinic Agent - The combined use of (R)-5-(2-{[2-(2-ethoxyphenoxy)ethyl]amino}propyl)-2-methoxybenzene-1-sulfonamide (tamsulosin), or its pharmaceutically acceptable salt, and (1S)-1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylic acid (3R)-quinuclidin-3-yl ester (solifenacin), or its pharmaceutically acceptable salt, for the preparation of a medicament for the improvement of lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH) with a substantial storage component is provided. | 10-10-2013 |
20130317059 | PHARMACEUTICAL COMPOSITION COMPRISING PYRIDONE DERIVATIVES - A pyridone derivative compound and a pharmaceutically acceptable salt, isomer, solvate or hydrate thereof, and a preventive or therapeutic pharmaceutical composition for cognitive disorders that includes the pyridone derivative compound or a pharmaceutically acceptable salt, isomer, solvate or hydrate thereof. | 11-28-2013 |
20130338186 | AMIDES OF ACETIC AND PROPIONIC ACIDS - The invention relates to novel amides of acetic and propionic acids, methods for production and use thereof for the production of medicaments for the treatment and/or prophylaxis of diseases and for improving perception, concentration, learning ability and memory. | 12-19-2013 |
20140024673 | (2S,3R)-N-(2-((3-PYRIDINYL)METHYL)-1-AZABICYCLO[2.2.2]OCT-3-YL)BENZYOFURN-- 2-CARBOXAMIDE, NOVEL SALT FORMS, AND METHODS OF USE THEREOF - The present invention relates to (2S,3R)—N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide, novel salt forms thereof, methods for its preparation, novel intermediates, and methods for treating a wide variety of conditions and disorders, including those associated with dysfunction of the central and autonomic nervous systems. | 01-23-2014 |
20140024674 | TRPM5 INHIBITORS SUPPORT BODY WEIGHT REDUCTION WITHOUT REDUCING FOOD INTAKE - The present invention relates to the field of weight management and the prevention and/or treatment of metabolic disorders. In particular, the present invention provides a composition comprising at least one Trpm5 inhibitor which is effective in the treatment of prevention of metabolic disorders or risk factors thereof, such as overweightness or obesity, without having to reduce food intake below metabolic needs. | 01-23-2014 |
20140051721 | STABLE CRYSTALLINE SALT OF (R)-3-FLUOROPHENYL-3,4,5-TRIFLUOROBENZYLCARBAMIC ACID 1-AZABICYCLO [2.2.2]OCT-3-YL ESTER - The present invention refers to a stable crystalline salt of (R)-3-fluorophenyl-3,4,5-trifluorobenzylcarbamic acid 1-azabicyclo [2.2.2]oct-3-yl ester and its use as medicament, in particular for the treatment of urinary incontinence or other diseases involving genitourinary disorders | 02-20-2014 |
20140080863 | MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS - Muscarinic Acetylcholine Receptor Antagonists and methods of using them are provided. | 03-20-2014 |
20140100246 | ACLIDINIUM FOR USE IN IMPROVING THE QUALITY OF SLEEP IN RESPIRATORY PATENTS - The present invention provides aclidinium or any of its steroisomers or mixture of stereoisomers, or a pharmaceutically acceptable salt or solvate thereof, for improving the quality of sleep in respiratory patients. | 04-10-2014 |
20140148479 | Treatment of Cognitive Disorders with (R)-7-Chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-Carboxamide and Pharmaceutically Acceptable Salts Thereof - (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide has been found to have procognitive effects in humans at unexpectedly low doses. Thus, (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof can be used at unexpectedly low doses to improve cognition. | 05-29-2014 |
20140155427 | NOVEL COMPOUNDS - Compounds of formula (I) described herein are inhibitors of the phosphodiesterase 4 (PDE4) enzyme and muscarinic M3 receptor antagonists and are useful for the prevention and/or treatment of diseases of the respiratory tract characterized by airway obstruction. | 06-05-2014 |
20140155428 | NOVEL COMPOUNDS - Compounds of formula (I) defined herein are both inhibitors of the phosphodiesterase 4 (PDE4) enzyme and muscarinic M3 receptor antagonists and are useful for the prevention and/or treatment of a disease of the respiratory tract characterized by airway obstruction. | 06-05-2014 |
20140155429 | Treatment of Cognitive Disorders with Certain Alpha-7 Nicotinic Acid Receptor Agonists in Combination with Nicotine - A method for improving cognition comprising co-administering to a subject an alpha 7 agonist, or a pharmaceutically acceptable salt thereof and a tobacco-free nicotine dosage is described together with related compositions. | 06-05-2014 |
20140155430 | TREATMENT OF COGNITIVE DISORDERS WITH (R)-7-CHLORO-N-(QUINUCLIDIN-3-YL)BENZO[B]THIOPHENE-2-CARBOXAMIDE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF - (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide has been found to have procognitive effects in humans at unexpectedly low doses. Thus, (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof can be used at unexpectedly low doses to improve cognition. | 06-05-2014 |
20140163065 | PREPARATION AND THERAPEUTIC APPLICATIONS OF (2S, 3R)-N-2-((3-PYRIDINYL)METHYL)-1-AZABICYCLO[2.2.2]OCT-3-YL)-3,5-DIFLUOROBE- NZAMIDE - The present invention relates to compounds that bind to and modulate the activity of neuronal nicotinic acetylcholine receptors, to processes for preparing these compounds, to pharmaceutical compositions containing these compounds, and to methods of using these compounds for treating a wide variety of conditions and disorders, including those associated with dysfunction of the central nervous system (CNS). | 06-12-2014 |
20140163066 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY - Compounds of formula (I) defined herein act both as muscarinic receptor antagonists and beta2 adrenergic receptor agonists and are useful for the prevention and/or treatment of broncho-obstructive or inflammatory diseases. | 06-12-2014 |
20140163067 | Methods of Treatment of Limited Cognitive Impairment - A method for improving or treating a Limited Cognitive Impairment (LCI) comprising administering to a subject a compound of the invention, or a pharmaceutically acceptable salt thereof is described together with related compositions. | 06-12-2014 |
20140179734 | ADHESIVE SKIN PATCH CONTAINING SEROTONIN RECEPTOR ANTAGONIST DRUG - Provided is a transdermal absorption-type patch containing a serotonin receptor antagonist, which has a short transdermal absorption delay time (lag time), and in which the maximum transdermal permeation rate of the drug can be reached within a short time and the drug can disappear from circulating blood rapidly. That is, provided is a patch containing a serotonin receptor antagonist, wherein the patch contains an adhesive layer comprising a non-functional acrylic adhesive, a water-soluble organic amine, a fatty acid ester, and a serotonin receptor antagonist such as granisetron as an active ingredient. | 06-26-2014 |
20140249179 | Crystalline Form of (R)-7-Chloro-N-(Quinuclidin-3-YL)benzo[B]thiophene-2-Carboxamide Hydrochloride Monohydrate - Crystalline Forms I and II of (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate and compositions, methods of manufacture and therapeutic uses thereof are described. | 09-04-2014 |
20140288118 | N-BIARYLAMIDES - The invention relates to N-biarylamides, methods for production and use thereof for the production of medicaments for the treatment and/or prophylaxis of diseases and for improvement in cognition, concentration power, learning power and/or memory. | 09-25-2014 |
20140371264 | MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS - Muscarinic Acetylcholine Receptor Antagonists and methods of using them are provided. | 12-18-2014 |
20150045386 | (2S,3R)-N-2-3-PYRIDINYLMETHYL-1-AZABICYCLO 2.2.2 OCT-3-YL BENZOFURAN-2-CARBOXAMIDE, NOVEL SALT FORMS, AND METHODS OF USE THEREOF - The present invention relates to (2S,3R)—N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide, novel salt forms thereof, methods for its preparation, novel intermediates, and methods for treating a wide variety of conditions and disorders, including those associated with dysfunction of the central and autonomic nervous systems. | 02-12-2015 |
20150065537 | AZABICYCLIC CARBAMATES AND THEIR USE AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS - The invention relates to novel benzothiophene-, benzofuran-, and indole ureas and to the use thereof for producing medicaments for the treatment and/or prophylaxis of diseases and for improving perception, concentration, learning, and/or memory. | 03-05-2015 |
20150105421 | PREPARATION AND THERAPEUTIC APPLICATIONS OF (2S,3R)-N-2-((3-PYRIDINYL)METHYL)-1-AZABICYCLO[2.2.2]OCT-3-YL)-3,5-DIFLUO- ROBENZAMIDE - The present invention relates to compounds that bind to and modulate the activity of neuronal nicotinic acetylcholine receptors, to processes for preparing these compounds, to pharmaceutical compositions containing these compounds, and to methods of using these compounds for treating a wide variety of conditions and disorders, including those associated with dysfunction of the central nervous system (CNS). | 04-16-2015 |
20150126546 | Treatment of Cognitive Disorders with Certain Alpha-7 Nicotinic Acid Receptors in Combination with Acetylcholinesterase Inhibitors - A method for improving cognition comprising administering to a patient (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide or a pharmaceutically acceptable salt thereof and an acetylcholinesterase inhibitor is described together with related compositions. | 05-07-2015 |
20150126547 | Methods of Maintaining, Treating or Improving Cognitive Function - A method of administering an effective amount of (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide, or a pharmaceutically acceptable salt thereof, to a patient in need thereof. | 05-07-2015 |
20150133491 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY - Compounds of formula (I) described herein act both as muscarinic receptor antagonists and beta2 adrenergic receptor agonists and are useful for the prevention and/or treatment of broncho-obstructive or inflammatory diseases. | 05-14-2015 |
20150299163 | COMPOUNDS FOR USE IN THE TREATMENT OF PARASITIC DISEASES - The present invention relates to compounds useful for treating parasitic diseases, which are infectious diseases caused or transmitted by a parasite. Compounds of the invention are particularly active against the causative pathogens in malaria. Such compounds are selective inhibitors of parasitic histone deacetylase (PfHDAC) and suppress the growth of parasites, such as | 10-22-2015 |
20150313884 | USE OF ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS - The invention concerns the use of certain alpha 7 nicotinic acetylcholine receptor agonist for the facilitation of emergence from general anesthesia. | 11-05-2015 |
20150352091 | AMINOESTER DERIVATIVES - Compounds of formula (I), defined herein, are both phosphodiesterase 4 (PDE4) enzyme inhibitors and muscarinic M3 receptor antagonists and are useful for the prevention and/or treatment of a disease of the respiratory tract. | 12-10-2015 |
20160002220 | MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS - Methods of using Muscarinic Acetylcholine Receptor Antagonists are provided. | 01-07-2016 |
20160008337 | Compositions and Methods for the Treatment of Presbyopia | 01-14-2016 |
20160009706 | QUINUCLIDINES FOR MODULATING ALPHA 7 ACTIVITY | 01-14-2016 |
20160009707 | CRYSTALLINE FORM OF (R)-7-CHLORO-N-(QUINUCLIDIN-3-YL)BENZO[B]THIOPHENE-2-CARBOXAMIDE HYDROCHLORIDE MONOHYDRATE | 01-14-2016 |
20160022651 | AMIDES OF ACETIC AND PROPIONIC ACIDS - The invention relates to novel amides of acetic and propionic acids, methods for production and use thereof for the production of medicaments for the treatment and/or prophylaxis of diseases and for improving perception, concentration, learning ability and memory. | 01-28-2016 |
20160022668 | APPLICATION OF CINCHONA ALKALOID DERIVATIVES AS CYTOTOXIC COMPOUNDS - 9-O-propargyl ethers of cinchona alkaloids of general formula represented by formula 1 | 01-28-2016 |
20160082002 | METHOD OF REGULATING CARDIAC ARRHYTHMIAS - A method of treating cardiac arrhythmia. The method comprises oral ingestion of liquid comprising quinine, or the stereoisomer quinidine. The liquid, which may be a beverage, is consumed in a volume that provides quinine equivalent to consumption of not less than 2 milligrams and not more than 80 milligrams per day. This dosage has been found to be effective in treating cardiac arrhythmia and inhibiting physiologically damaging atrial fibrillation, and the complications thereof. | 03-24-2016 |
20160095840 | COMBINATIONS OF A MUSCARINIC RECEPTOR ANTAGONIST AND A BETA-2 ADRENORECEPTOR AGONIST - Combinations of a muscarinic acetylcholine receptor antagonist and a beta 2 agonist for inhaled administration via the nose or mouth, and methods of using them are provided. | 04-07-2016 |
20160145253 | SALTS OF AZA-BICYCLIC DI-ARYL ETHERS AND METHODS TO MAKE THEM OR THEIR PRECURSORS - The present invention relates to salts of (R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane, to methods for making them or their precursors, to pharmaceutical compositions comprising them, and to their use as medicaments. | 05-26-2016 |
20160193193 | Compositions and Methods for the Treatment of Presbyopia | 07-07-2016 |
20160193194 | Compositions and Methods for the Treatment of Presbyopia | 07-07-2016 |
20170231974 | Combined Use of an Alpha-Adrenergic Receptor Antagonist and an Anti-Muscarinic Agent | 08-17-2017 |
20190144386 | INHIBITORS OF INTEGRIN ALPHA 5 BETA 1 AND METHODS OF USE | 05-16-2019 |